SCHEMBL4144153

SCHEMBL4144153

O=C(CCO)Nc1cc2c(/C=C/c3ccc(F)cc3)n[nH]c2cc1F

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
AURKA O14965 7/20 0.51
AURKB Q96GD4 5/20 0.46
KDR P35968 9/20 0.45
GSK3B P49841 3/20 0.41
CYP1A2 P05177 1/20 0.40
CSF1R P07333 1/20 0.39
PDGFRB P09619 1/20 0.39
KIT P10721 1/20 0.39
PDGFRA P16234 1/20 0.39
CHEK1 O14757 2/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
FGFR1 P11362 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4144156 1.00 AURKA (0.51) AURKAAURKBKDRGSK3BCYP1A2
SCHEMBL27604791 0.89 AURKA (0.53) AURKAAURKBKDRGSK3BCSF1R
SCHEMBL4146342 0.88 AURKA (0.52) AURKAAURKBKDRCSF1RPDGFRB
SCHEMBL4146345 0.88 AURKA (0.52) AURKAAURKBKDRCSF1RPDGFRB
SCHEMBL4146538 0.87 AURKA (0.52) AURKAAURKBKDRGSK3BCSF1R
SCHEMBL4146534 0.87 AURKA (0.52) AURKAAURKBKDRGSK3BCSF1R
SCHEMBL4302432 0.87 AURKA (0.52) AURKAAURKBKDRGSK3BCSF1R
SCHEMBL4302429 0.87 AURKA (0.52) AURKAAURKBKDRGSK3BCSF1R
SCHEMBL4137549 0.86 AURKA (0.52) AURKAAURKBKDRGSK3BCSF1R
SCHEMBL4137555 0.86 AURKA (0.52) AURKAAURKBKDRGSK3BCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054397-A1 PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND OHI NORIHITO 2009-02-26 US disclosed
US-7429609-B2 Pyrazole compound and medicinal composition containing the same EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-09-30 US disclosed
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-24 US disclosed
US-20050208582-A1 Pyrazole compounds and pharmaceutical compositions comprising the compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-09-22 US disclosed
CN-1656079-A Pyrazole compounds and pharmaceutical compositions containing the same EISAI CO LTD (JP) 2005-08-17 CN disclosed
EP-1510516-A1 PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME Eisai Co., Ltd. (JP) 2005-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054397-A1 PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND CNKSR1, NR3C2, CSNK2B AURKA 726/4885AURKB 608/4885KDR 932/4885
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same CNKSR1, NR3C2, CSNK2B AURKA 710/4885AURKB 579/4885KDR 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.